CAR-DC Vaccine and ICIs in Local Advanced/Metastatic Solid Tumors

Launched by CHINESE PLA GENERAL HOSPITAL · Nov 29, 2022

Keywords

ClinConnect Summary

This clinical trial is studying a new treatment for adults with certain types of advanced or spreading solid tumors that have specific genetic changes, particularly in a gene called KRAS. The treatment involves a specialized vaccine designed to help the immune system recognize and attack cancer cells by targeting a protein called EphA2. The researchers want to find out if this vaccine, when combined with other immune therapies, is safe and effective in helping the body’s immune response to fight the cancer.

To participate in this trial, you need to be between 18 and 75 years old and have a confirmed diagnosis of specific solid tumors that show high levels of EphA2 and KRAS mutations. You should have already tried standard treatments without success or not have access to them. Participants will receive the experimental treatment and will need to complete regular visits for assessments. It’s important that you are able to provide informed consent and are willing to undergo some tests to monitor your health throughout the study. If you're interested and meet the criteria, please reach out to the research team for more information.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Age 18-75 (inclusive).
• • 2. ECOG performance status ≤2 and Estimated life expectancy of more than 3 months.
• • 3. Local advanced/metastatic solid tumors confirmed by histopathology or cytology with documentation of tumor EphA2 positive (≥20%) and KRAS mutation (G12V or G12D or G12C) within 6 months prior to screening. The second malignancy is allowed.
• • 4. No clinical response to standard frontline therapy, or no standard therapy exists. Patients who have declined standard therapy or have no access to standard therapy may be enrolled and the reasons for lack of access need to be documented. Previous treatment with anti-PD-1/PD-L1 antibodies or anti-CTLA4 antibody are allowed, regardless of the level of PD-1/PD-L1 expression, dMMR and TMB.
• • 5. At least one measurable lesion at baseline per RECIST version 1.1.
• • 6. Adequate organ function as defined by the following criteria: ANC ≥1000 cells/μL; Platelet count ≥80,000/μL; Hemoglobin ≥8.0 g/dL; Serum AST and serum ALT, ≤3.0 x ULN (≤5 x ULN for patients with liver metastases); Total serum bilirubin ≤3.0 x ULN); Serum creatinine ≤2 x ULN or creatinine clearance of ≥45 mL/min.
• • 7. Willing to undergo either excised or large-needle lymph node or tissue biopsy, or provide formalin-fixed paraffin-embedded (FFPE) tumor tissue block or freshly cut unstained slides.
• • 8. Willing to complete all scheduled visits and assessments at the institution administering therapy.
• • 9. Able to read, understand and provide written informed consent.
• Exclusion Criteria:
• • 1. Having KRAS (G12V or G12D or G12C) germline mutation.
• • 2. Active central nervous system disease involvement (but allow patients with prior brain metastases treated at least 4 weeks prior to enrollment that are clinically stable and do not require intervention), or prior history of NCI CTCAE Grade ≥3 drug-related CNS toxicity.
• • 3. Prior organ allograft transplantations or allogeneic hematopoietic stem cell transplantation.
• • 4. Evidence of active uncontrolled viral, bacterial, or systemic fungal infection.
• • 5. Known positive test result for human immunodeficiency virus (HIV) or acquired immune deficiency syndrome (AIDS).
• • 6. Active infection of hepatitis B virus (HBV), or hepatitis C virus (HCV).
• • 7. Patients with history (within the last 5 years) or risk of autoimmune disease who have immunosuppressive medications or immunosuppressive doses of systemic corticosteroids (\>10 mg/day prednisone or equivalent) within 28 days prior to enrollment. However, patients who received a short course of corticosteroids (eg, premedication prior to antibody drug) will be eligible for study entry.
• • 8. Major trauma or major surgery within 4 weeks prior to enrollment.
• • 9. Previous treatment involving KRAS mutant (G12V or G12D or G12C) and EphA2.
• • 10. Systemic chemotherapy and other intervene within 2 weeks prior to vaccination.
• • 11. Being participating or withdrew any other trials within 4 weeks.
• • 12. Any serious underlying medical (eg, pulmonary, renal, hepatic, gastrointestinal, or neurological) or psychiatric condition or any issue that would limit compliance with study requirements.
• • 13. Vaccination within 30 days of study enrollment.
• • 14. Pregnant, lactating, or breastfeeding females.
• • 15. Researchers believe that other reasons are not suitable for clinical trials.